R&D Pipeline

Indicated for the treatment of postmenopausal women with osteoporosis at high risk of fracture. As the only bone-forming agent available domestically, it promotes new bone formation, significantly increases bone density, and improves bone quality. The treatment demonstrates a significant reduction in vertebral and non-vertebral fracture risks, interrupts the fracture cascade effect, and lowers the risk of subsequent fractures following an initial osteoporotic fracture.

The Group is actively preparing for the U.S. FDA submission of Bogutai®. The product is expected to benefit from an accelerated regulatory review process, with FDA approval anticipated to be received and launch in the U.S. in 2027. Bogutai® is expected to become the Group’s first product to achieve overseas commercialization.

BMP2 biomedical material UB‑107, a key growth factor in regenerative medicine, recruits and induces mesenchymal stem cells (MSCs) to differentiate into osteogenic lineages. It is widely used clinically in bone defect reconstruction and spinal fusion surgeries.Using the group's proprietary ECO‑KSFA® technology platform, the Group has established a manufacturing process for the BMP2 active pharmaceutical ingredient (API). The product targets multiple orthopedic applications, including critical-sized bone defects, non-union fractures, and interbody spinal fusion.

Developed in collaboration with Great Bay Bio (GBB) and TigerMed Pebble Accelerator, this innovative weight-loss therapeutic aims to transform obesity treatment. In 2025, the Group co-developed with GBB a potentially first-in-class dual-target antibody for obesity, designed to promote fat loss while preserving muscle mass. During the Period, In a DIO mouse study, the lead candidate outperformed a clinical-stage benchmark combination in overall weight reduction, fat loss and body-composition improvement, while also mitigating lean-mass loss associated with standard weight-loss therapy, supporting its potential to deliver higher-quality weight loss.

Using the newly operational Blow-Fill-Seal (BFS) production line in Dongguan, The Group is accelerating development of next-generation GeneSoft® products, including 0.5mL BFS single-dose (daily disposable) format and 3mL BFS multi-dose preservative free format. The 0.5mL single-dose EGF ophthalmic formulation, indicated for the treatment of corneal epithelial defects, is expected to be commercially launched by the end of 2027.

UB102 is a novel bispecific nanobody designed to simultaneously target VEGF-A and Ang-2 for the treatment of ocular diseases such as wet age-related macular degeneration(wAMD). Encouraging in vitro data have been generated for the program, demonstrating substantially higher target-binding affinity and cellular blockade activity against bothVEGF-A and Ang-2 compared with faricimab, supporting its potential for a best-in-class profile in dual-pathway inhibition.

Building on UB102, a potent anti-inflammatory module targeting a key cytokine pathway has also been developed, providing the potential to integrate angiogenesis and inflammation control within a novel tri-specific therapeutic approach. Together, these findings provide a foundation for the development of a potentially best-in-class tri-specific format and support the exploration of partnership and co-development opportunities with leading global pharmaceutical and biotechnology companies.

The Group’s proprietary EGF/FGF compound gel has successfully completed formulation research and preliminary efficacy trials. Unlike conventional liquid-based formulations, this smart, thermosensitive gel provides a sustained-release mechanism that maintains a moist wound-healing environment, accelerates tissue repair, and minimizes scarring. During the Period, the project transitioned into pilot-scale production while advancing non-clinical studies for deep second-degree burns, scalds, and chronic wound healing, with planned clinical indications expanding to include diabetic foot ulcers.